Chemotherapy Decision-Making in Early Breast Cancer

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Russ Conroy

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Jorge Nieva, MD

July 14th 2025

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

EC Approves Ibrutinib Plus Chemoimmunotherapy +/- ASCT in Untreated MCL

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.

Tim Cortese

Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma

Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.

Related Content

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Russ Conroy

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Jorge Nieva, MD

July 14th 2025

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

EC Approves Ibrutinib Plus Chemoimmunotherapy +/- ASCT in Untreated MCL

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Tim Cortese